A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

Ozempic, a diabetes medication by Novo Nordisk, has gained popularity for its weight loss effects, sparking debate.

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

The Beijing IP Court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and ...

Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

Researchers from Loyola University Chicago are adding to the growing evidence suggesting that medications like Ozempic can ...

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...